<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202524</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8009</org_study_id>
    <nct_id>NCT03202524</nct_id>
  </id_info>
  <brief_title>Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis</brief_title>
  <official_title>Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Large volume paracentesis with albumin administration is the standard of care for patients
      with refractory ascites complicating end-stage liver disease. However, the use of albumin is
      frequently limited due to expense and occasional short supply. The goal of this study is to
      demonstrate if the administration of fresh frozen plasma (FFP) is as effective as albumin for
      volume expansion at the time of a large volume paracentesis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-Paracentesis Circulatory Dysfunction (PPCD)</measure>
    <time_frame>6 Days</time_frame>
    <description>The development of PPCD is diagnosed by an increase in plasma renin activity of more than 50% of baseline to &gt; 4 ng/mL/h on the 6th day post paracentesis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Ascites Hepatic</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fresh Frozen Plasma (FFP)</intervention_name>
    <description>FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.</description>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Cirrhosis of the liver based on biopsy or clinical and radiographic criteria

          3. Ability to provide informed consent (Grade 0 to 1 HE)

          4. Grade 3 ascites or refractory ascites

          5. Ascites requiring frequent large volume paracentesis of at least 5 liters at least
             once a month

          6. No diuretic use

        Exclusion Criteria:

          1. Inability to obtain informed consent

          2. Age less than 18

          3. Hepatic Encephalopathy Grade &gt; 1

          4. Septic shock

          5. Active infection

          6. Respiratory failure

          7. Heart failure with reduced ejection fraction of â‰¤ 50%

          8. Moderate or severe pulmonary hypertension

          9. History of stroke

         10. Unstable coronary artery disease

         11. Chronic kidney disease (GFR &lt;60)

         12. GI bleed within 2 weeks

         13. Any licorice within 2 weeks of starting the study

         14. Any Beta Blocker use within the last 2 weeks

         15. Any diuretic use within 2 weeks

         16. Absence of paracentesis within 2 weeks

         17. Absence of volume expanders within 2 weeks

         18. INR &gt; 1.7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Sigal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques C Beauvais, MD</last_name>
    <phone>347-610-7305</phone>
    <email>jabeauva@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel Sigal, MD</last_name>
    <phone>718-920-4768</phone>
    <email>ssigal@montefiore.org</email>
  </overall_contact_backup>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Samuel H. Sigal</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Paracentesis</keyword>
  <keyword>Albumin</keyword>
  <keyword>Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data collected during the study will only be shared with researchers approved to key-personnel on the study protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

